Design Therapeutics Inc (DSGN)
3.30
-0.05
(-1.49%)
USD |
NASDAQ |
Jun 25, 16:00
3.30
0.00 (0.00%)
After-Hours: 20:00
Design Therapeutics Research and Development Expense (Annual): 57.06M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 57.06M |
| December 31, 2022 | 48.61M |
| December 31, 2021 | 24.78M |
| Date | Value |
|---|---|
| December 31, 2020 | 6.06M |
| December 31, 2019 | 1.654M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
1.654M
Minimum
2019
57.06M
Maximum
2023
27.63M
Average
24.78M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Biogen Inc | 2.462B |
| AbbVie Inc | 7.675B |
| PTC Therapeutics Inc | 666.56M |
| Revance Therapeutics Inc | 79.41M |
| Context Therapeutics Inc | 17.78M |